Aileron Therapeutics, Inc. Banner Image

Aileron Therapeutics, Inc. has reached its limit for free report views

Work for Aileron Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Aileron Therapeutics, Inc.

  • Ticker ALRN
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Aileron Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Watertown, Massachusetts
Aileron Therapeutics (NASDAQ:ALRN) is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable targets using their proprietary platform of stabilized cell-permeating peptides. Their lead product candidate, ALRN-6924, is a cell-permeatingMore peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2. Their focus at Aileron is the clinical development of ALRN-6924 to protect cancer patients against chemotherapy-induced toxicities, a novel concept they call “chemoprotection.”
Aileron Therapeutics, Inc.

Most Recent Annual Report

Aileron Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Aileron Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports